Takeda acquiring Ariad Pharmaceuticals for $5.2B: 5 key points

Japan's Takeda Pharmaceutical is acquiring Cambridge, Mass.-based Ariad Pharmaceuticals for $5.2 billion to add to its oncology pipeline, Reuters reports.

Here's what you should know.

1. Takeda agreed to pay Ariad's shareholders $24 per share.

2. Ariad's stocks increased 72 percent from $13.82 to $23.78 when the deal broke on Jan. 9, 2017.

3. A number of Takeda patents will expire in the coming year fueling Takeda's shopping spree.

4. Takeda is primarily acquiring Ariad's leukemia drug, Iclusig. Takeda expects the drug to generate between $170 million to $180 million in sales.

5. Takeda will take on $4 billion in debt to pay for the transaction.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast